Full-Time
Senior Infrastructure Engineer
Posted on 10/31/2025
Deep Genomics
51-200 employees
AI-driven RNA-based drug discovery platform
No salary listed
Toronto, ON, Canada
Hybrid
 DevOps & Infrastructure (3) |
|---|
| , , |
- 5+ years of experience working as an Infrastructure Engineer, DevOps/MLOps Engineer, or SRE.
- Proficient in architecting and managing infrastructure using Infrastructure as Code tools (e.g. Terraform and Helm).
- Deep expertise in containerization and orchestration technologies like Docker and Kubernetes.
- Strong understanding of identity management and security best practices.
- Extensive experience designing, implementing, and maintaining CI/CD pipelines (e.g. CircleCI).
- Demonstrated experience with mentoring and elevating other team members' skills to adhere to engineering and DevOps best practices.
- Manage infrastructure for software, data, and ML platforms, both in the cloud and our on-premises GPU clusters.
- Design and implement integrations between infrastructure components (containing internal and 3rd party systems) to ensure seamless flow of data in a robust, reliable, and secure manner.
- Streamline and/or automate operational tasks such as infrastructure provisioning, configuration management, and application deployment.
- Implement and manage robust monitoring, logging, and alerting for key infrastructure components.
- Collaborate closely with engineers, scientists, security, and compliance teams to implement and promote DevSecOps principles across the organization.
- Experience with Python/Shell scripting and automation tools.
- Experience managing infrastructure on Google Cloud Platform (GCP).
- Hands-on experience with modern ML platforms and frameworks (e.g. Weights & Biases, Metaflow, MLflow, Ray) and familiarity with the operational challenges of scaling ML workloads.
- Experience designing and operating hybrid-cloud architectures that span on-premises and cloud environments, with an emphasis on resilience, observability, and cost optimization.
- Familiarity with secrets management, zero-trust architectures, and secure-by-default design patterns in regulated or privacy-sensitive environments.
Deep Genomics uses AI to speed up drug discovery by studying RNA biology and how genetic variants affect gene expression. Its main product, the AI Workbench, analyzes genomic data to identify novel drug targets and potential therapies for genetic diseases. It differentiates itself by focusing on RNA-level mechanisms and expanding its target discovery capabilities across versions. The goal is to provide a license-ready platform that yields actionable targets for collaboration or internal development, accelerating therapies for patients with genetic conditions.
Company Size
51-200
Company Stage
Series C
Total Funding
$236.8M
Headquarters
Toronto, Canada
Founded
2014
Simplify's Take
What believers are saying
- $180M Series C from SoftBank funds four clinical programs by 2023.
- Thong Q. Le and Paul Sekhri joined board October 6, 2025, boosting expertise.
- New Cambridge lab and Toronto expansion enhance AI-driven RNA research capacity.
What critics are saying
- Recursion's SuperTMLM outperforms BigRNA, stealing pharma partners within 6-12 months.
- Insilico advances 3 RNA candidates to Phase II, capturing Sanofi deals in 12-18 months.
- $180M cash burns out in 18-24 months, forcing dilutive down-round.
What makes Deep Genomics unique
- BigRNA is world's first AI foundation model decoding RNA biology for therapeutics.
- AI Workbench 2.0 expanded RNA splicing and expression mechanisms since 2020.
- Proprietary platform enables pharma partners to leverage private data securely.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↓ -1%2 year growth
↑ 1%Thong Q. Le and Paul Sekhri join Board of Directors at Deep Genomics. Pictured: Thong Q. Le (left) and Paul Sekhri (right), the newest members of the Board of Directors for Deep Genomics Cambridge, Mass. / Toronto, CA - October 6, 2025 - Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of respected business leaders Thong Q. Le and Paul Sekhri to its Board of Directors. "We feel incredibly lucky to have the talents of Thong and Paul join our Board of Directors", said Brian O'Callaghan, Chief Executive Officer of Deep Genomics. "Their collective decades of experience shaping the life sciences and biotechnology industry will be invaluable as we continue towards our mission of delivering AI-powered genetic medicines to patients." Thong Q. Le brings more than two decades of investment experience in the life sciences industry, with a strong track record of making impactful investments that improve lives, shaping effective investment strategies and aiding deal-making processes. Mr. Le currently serves as investment director and managing partner of the Strategic Investment Fund (SIF) for the Gates Foundation. Mr. Le also serves as chairman of Accelerator Life Science Partners (ALSP), a venture capital firm focused on developing next-generation life science companies. He has served as a director, founding president and CEO of more than a dozen ALSP portfolio companies, including Petra Pharma, Rodeo Therapeutics and Lodo Therapeutics. Mr. Le currently serves on several private biotech and nonprofit organization boards. "In my time working with this industry, I've seen firsthand how the right combination of science, technology and leadership can transform what's possible in drug discovery," said Mr. Le. "Deep Genomics has all of those ingredients, and I'm thrilled to have this opportunity to help guide its continued growth." Paul Sekhri is the current Chair, President and CEO of vTv Therapeutics Inc., Chair of the Board of Resolution Therapeutics, and Executive Chair of Violet Therapeutics Inc., bringing more than 35 years of experience in business development and strategy across top life sciences, pharmaceutical and biotechnology companies. Most recently, he served as President and CEO of eGenesis Inc. and Lycera Corp. Previously, Mr. Sekhri held senior leadership positions at Sanofi, Teva Pharmaceuticals, TPG Biotech, Cerimon Pharmaceuticals Inc., Ariad Pharmaceuticals and Novartis. He currently serves on the Board of Veeva Systems, AdhereTech Inc., Kayothera; is Chair of Young Concert Artists (YCA), and sits on the Advisory Council of the New York Philharmonic. Mr. Sekhri commented, "I am excited to be joining the Deep Genomics Board at such a pivotal time in therapeutics, and I remain inspired by their ability to advance a new generation of medicines with the power of AI. I look forward to contributing to such important TechBio advancements alongside this talented team." To learn more about Deep Genomics' work and its groundbreaking impact in the realm of genomic R&D, visit www.deepgenomics.com. For those interested in joining this team of TechBio innovators, visit https://www.deepgenomics.com/careers/. About Deep Genomics Deep Genomics is a multidisciplinary team of AI and biology scientists dedicated to pioneering a new era of genomic research and development through its AI foundation models platform. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-changing genetic medicines to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow Deep Genomics Inc. on LinkedIn and Twitter.
Under O'Callaghan's leadership, Deep Genomics launched additional proprietary AI foundation models that work alongside BigRNA, including DeepADAR for RNA editing and REPRESS, which accurately predicts microRNA (miRNA) binding and mRNA degradation directly from RNA sequences.
Deep Genomics, a Canadian biotech company, closed a $180 million Series C funding round led by Softbank, with investments from CPPIB, Fidelity, and others. The company, supported by Amplitude Ventures, uses AI to revolutionize drug discovery, focusing on RNA therapeutics. The funding will expand their AI workbench and pipeline, aiming to advance four programs into the clinic by 2023.
Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System
For instance, Deep Genomics unveiled BigRNA, a pioneering AI foundation model for uncovering RNA biology and therapeutics.